This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
by Arpita Dutt
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
by Arpita Dutt
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.
Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.
Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?
by Zacks Equity Research
Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.
Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.
3 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News
by Arpita Dutt
Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?
by Zacks Equity Research
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.
Concert Pharmaceuticals Plunges on Patent Petition Setback
by Zacks Equity Research
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
Can Biotech Keep Last Year's Momentum Alive in 2018?
by Zacks Equity Research
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU
by Zacks Equity Research
Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
by Arpita Dutt
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Galapagos Reports Topline Data From Osteoarthritis Study
by Zacks Equity Research
Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.
Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?
by Zacks Equity Research
Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.
Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
by Arpita Dutt
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
by Arpita Dutt
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
5 Hot Stocks Driving the Nasdaq ETF Rally
by Sweta Killa
Inside the top performing stocks of the Nasdaq ETF.
Proteostasis Stock Surges on Positive Data From CF Studies
by Zacks Equity Research
Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.
Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs
by Arpita Dutt
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.